Biodexa Pharmaceuticals
BDRX
5 hedge funds and large institutions have $28.1K invested in Biodexa Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
4% less capital invested
Capital invested by funds: $29.3K → $28.1K (-$1.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$41.3K |
| 2 |
GI
GAMMA Investing
Foster City,
California
|
+$5.07K |
| 3 |
Morgan Stanley
New York
|
+$2.45K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$525 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $24.9K | +$41.3K | +236 | +167% |
|
|
GI
2
GAMMA Investing
Foster City,
California
| $1.88K | +$5.07K | +29 | New |
|
|
3
Morgan Stanley
New York
| $924 | +$2.45K | +14 | New |
|
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $414 | +$525 | +3 | +100% |
|
|
CIM
5
Contravisory Investment Management
Norwell,
Massachusetts
| $53 | – | – | – |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $1 | – | – | – |
|
BDRX Hedge Fund Activity: Q1 2025 in Review
5 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2025, worth a combined $28.1K — down 4.1% from $29.3K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BDRX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $41.3K.
- 5 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2025, up from 3 in Q4 2024.
- Funds reported $28.1K of Biodexa Pharmaceuticals stock for Q1 2025, down 4.1% quarter-over-quarter.
- 2 funds opened new Biodexa Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +2 holders.
- The largest Biodexa Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $41.3K added.
Based on aggregated 13F filings for Q1 2025.